Perrigo Company plc (PRGO)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below the required floor of 3) — the upstream fundamental screen failed, so no bullish entry is permitted regardless of chart quality; the chart itself reads as a pullback-to-support continuation with a breakout-stop alternative above the 17.02 high, and both entry types were considered without being rejected on chart, volatility, liquidity, event or R/R grounds.
Company overview
Perrigo Company plc provides over-the-counter health and wellness products globally, operating through Consumer Self-Care Americas and International segments. Its offerings include respiratory, nutrition, digestive health, pain relief, oral care, and women's health products, among others. The company also provides contract manufacturing services and sells through various retail and e-commerce channels.
Fundamental
weakPerrigo is a leveraged company with declining revenue, litigation risks, and a dividend exceeding free cash flow.
Perrigo presents as a leveraged, cash-generative but structurally shrinking consumer self-care company whose reported losses are far worse than its cash economics — and whose cash economics are themselves weakening. The FY2025 10-K (filed 2026-02-26) reports a $1,425.4M net loss driven overwhelmingly by $1,363.1M of impairment charges, of which $1,325.3M was goodwill write-down across the CSCA and CSCI reporting units; the nine months to 2026-09-26 add a further $335.9M of impairments plus an expected $275.0M-$375.0M held-for-sale loss on the Infant Formula business in Q4 2026. Because operating cash flow has remained positive through that entire stretch (FY2025 $238.5M; trailing twelve months about $241M) and free cash flow is positive, the deeply negative GAAP net margin, negative ROE and distress-zone Altman Z are treated as non-cash, impairment-driven artifacts rather than evidence of a failing operating model. What is not an artifact is the operating trend: revenue fell 2.8% in FY2025 and 5.2% over the first nine months of 2026, reported gross margin compressed from 36.0% to 32.2%, Q3 2026 adjusted operating income fell 25.5% year over year, and management cut Core adjusted EPS guidance to $2.15-$2.35 while now guiding organic net sales to decline 2.7%-3.8%. Leverage is the binding constraint: $3,294.1M of debt against $436.6M of cash leaves roughly $2.86B of net debt, which management itself frames as about 4.0x adjusted EBITDA, with Moody's at Ba3 (negative), S&P at B+ (stable) and Fitch at BB (negative), and the 5.15% coupon cap already reached on the 2030 notes. The $1.16 annual dividend (roughly $161M) exceeds both FY2025 free cash flow of $145.1M and guided FY2026 free cash flow, so the headline yield is being part-funded by divestiture proceeds and balance-sheet capacity rather than by recurring cash generation. Valuation looks statistically cheap — about 1.26x EV/sales, 0.95x book and roughly 7x guided adjusted EPS — but this is a levered call on a declining, litigation-burdened franchise: approximately 245 talc lawsuits with more than 35 trials scheduled through Q1 2027, 50 pending price-fixing complaints from the divested Rx business, a securities class action naming the former and current CEOs and the CFO, an unresolved IRS transfer-pricing exposure of $25M-$128M, a CEO transition to an interim chief executive, and two reporting units (Women's Health, Skin Health) with goodwill passing margins below 10%. The discounted-cash-flow outputs implying several hundred percent of upside are treated as non-meaningful model extremes anchored on a cash-flow base flattered by roughly $260M a year of intangible amortization add-backs. The per-metric grade cross-check was skipped because the verdict sits on the bottom-of-scale borderline, where qualitative SEC disclosure dominates quantitative banding; had it been run mechanically it would have misled in both directions, banding a negative net-debt/EBITDA as strongest-in-class and graying out impairment-distorted margins. Net: the recurring, cash-based picture is a junk-rated, roughly 4x-levered, mid-single-digit-declining consumer franchise that does not cover its dividend from free cash flow — weak and inconsistent rather than outright distressed, and not a compelling fundamentals case until organic revenue stabilizes.
Sentiment
fairRecent divestiture news has been positively received, but operating momentum remains a concern.
Perrigo's dominant near-term driver is the announced (2026-10-29) agreement to divest its Infant Formula business to MeridianMade for up to $175M, which in-window coverage scored net-positive (+0.2 to +0.4) as a deleveraging and portfolio-simplification step, set against a mixed Q3 print (EPS ahead but net sales -5.2%, core adjusted operating margin compressed and core EPS/organic guidance cut) that the tape met with a modest rebound rather than a sell-off. The sentiment delta is indeterminate because the baseline window yielded only one scorable item, and the Red-Flag Screen is clean with no severe or moderate flag fired; the rewarded catalyst is already trailing and only partially priced with no forward-dated event, which keeps this a constructive mixed setup rather than a top-band one.
Technical
goodPerrigo's stock is in an uptrend above key moving averages, but fundamental issues prevent action.
Trend frame (bars through 2026-11-11, the run date): last 16.55 vs SMA20 16.11 (+2.7%), SMA50 15.09 (+9.7%), SMA200 12.50 (+32.4%), EMA9 16.27 (-0.7%), EMA21 15.93 (+3.9%), daily VWAP 16.5575 (at VWAP). The moving-average stack is fully bullish (SMA20 > SMA50 > SMA200) and all three are rising. Momentum frame: RSI14 61.07 (constructive, not overbought), Williams %R -24.74, MACD line 0.38 vs signal 0.36 with histogram +0.02 — the first positive histogram print after a sequence of negative readings running from 2026-10-28 (-0.04) through 2026-11-09 (-0.02), i.e. a fresh bullish crossover above the zero line. ADX14 23.42 and rising (19.79 on 2026-11-03) with price above all key averages, so trend strength is building in the up direction rather than against it. Volatility frame: ATR14 0.72 = 4.35% of the 16.55 price; StdDev20 0.38. Volume frame: avgDollarVolume20 $38,496,785 against the $5M floor; the last three regular sessions printed roughly $39.8M (2026-11-09), $26.0M (2026-11-10) and $15.9M (2026-11-11) of regular-session dollar volume, averaging about $27M against the $1.5M recent-liquidity floor; the +5.54% up session on 2026-11-09 traded 2.92M shares, above the following two down-day volumes of 2.11M and 1.30M. Structure: a steady advance from 15.06 (2026-10-09) to a 17.02 high (2026-11-09, also the 52-week high) followed by a two-session give-back to 16.55; the pullback is still holding above the SMA20 and well above the 2026-11-04 earnings-session low of 15.12. Event frame: the ticker-filtered fmp_earnings_calendar for 2026-10-12 through 2027-02-09 returned no earnings entries (no blackout, no in-window earnings); fmp_splits_calendar returned no splits; fmp_dividends_calendar returned a single ex-date at 2026-11-27 for $0.29, which at 1.75% of the $16.55 price is about 11 trading days out — far outside the +/-3-trading-day window, so the 1.5% dividend blackout does not fire — and although it falls inside the 15-trading-day holding window it is below the 3.0% holding-window threshold, so it does not gate either. Overnight-gap check over the stop-calculation window (regular-session opens/closes only): 2026-11-06 close 15.85 to 2026-11-09 open 16.06 = 1.32%; 2026-11-09 close 16.96 to 2026-11-10 open 16.67 = 1.71%; 2026-11-10 close 16.84 to 2026-11-11 open 16.58 = 1.54%; maximum 1.71%, under the 5% ceiling. Gate outcomes: price 16.55 <= 25.00 pass; 20-day liquidity pass; recent 3-session liquidity pass; overnight-gap pass; indicator-integrity pass (all 18 indicators loaded, none of the never-zero set is 0, sma50 and sma200 both present); stale-feed pass (last analyzed bar 2026-11-11 equals the run date, 0-trading-day lag); minimum-ATR floor pass (4.35% >= 1.0%); holding-window event pass (horizon 2026-12-03 from calc_trading_days_forward, no confirmed earnings, dividend below 3.0%); qualitative gate pass (qualitativeScore 3); fundamental override gate FAIL (fundamentalScore 2 < 3) — and the shadow branch is unavailable because the rendered shadow flag is false and the qualitative score is 3, not 2. Setup observation, not an emitted setup: the action most resembles a pullback_to_support continuation off the SMA20 16.11 / EMA21 15.93 shelf, with a breakout-stop alternative above the 2026-11-09 swing high of 17.02; both entry types were considered and neither is rejected on chart, volatility, liquidity or event grounds — the trade is suppressed solely by the fundamental floor, so no entry, protective stop, targets or R/R were computed and every plan field is zeroed.
In-depth analysis
Valuation
- P/E ratio is not meaningful due to negative earnings driven by non-cash impairments.
- EV/EBITDA is not meaningful due to negative EBITDA from impairment charges.
- EV/Sales ratio is healthy, suggesting a reasonable valuation relative to sales.
- PEG ratio is not meaningful as both earnings and growth rates are negative.
- The free cash flow yield is strong, indicating good cash generation relative to price.
Profitability
- ROIC is low, indicating limited returns on invested capital.
- EBITDA margin is not meaningful due to impairment-driven losses.
- Net margin is not meaningful due to impairment-driven losses.
- Gross margin is average, reflecting some cost pressures.
- ROE is not meaningful due to impairment-driven negative equity.
Growth
- Revenue growth is weak, showing a declining trend.
- EPS growth is not meaningful due to negative earnings.
- EBITDA growth is not meaningful due to negative earnings.
Risk
- Net debt to EBITDA is misleadingly strong due to negative EBITDA.
- Current ratio is strong, indicating good short-term liquidity.
- Beta is low, suggesting lower volatility relative to the market.
- Z-score indicates elevated financial risk, near distress levels.
- Interest coverage is low, indicating potential difficulty in covering interest expenses.
Discounted Cash Flow
Callout
The DCF models suggest extreme upside, but these outputs are considered non-meaningful due to inflated cash-flow assumptions and high leverage.
Trade plan
- Entry
- 0.00
- Protective stop
- 0.00
- Reward : risk
- 0.00 : 1
Catalysts to watch
- Ongoing process — timing TBD
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

